GlassScriptPhysician profile
Adeeba K Akhtar
NPI 1447264429
$5,646.13
in general payments reported to CMS, 2019-2025
43 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what 94% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $653 · 2021: $599 · 2022: $743 · 2023: $702 · 2024: $546 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,535 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.68 |
| Education | $103.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,386.39 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $798.25 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $596.13 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $379.55 | 2022-2025 | |
| Amarin Pharma, INC. | $282.72 | 2019-2020 | |
| Glaxosmithkline, LLC. | $257.40 | 2020-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.85 | 2021-2025 | Synjardy, Jardiance, Glyxambi |
| Eisai INC. | $216.62 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $177.05 | 2023-2025 | Gemtesa, Myfembree |
| Teva Pharmaceuticals USA, INC. | $165.87 | 2019-2025 | Austedo Xr |
| Pfizer INC. | $104.20 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $89.71 | 2019 | |
| Amgen INC. | $83.16 | 2023-2024 | Otezla, Repatha, Prolia |
| Astellas Pharma US INC | $70.70 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $56.14 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeeba Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.